Zacks Research Downgrades GE HealthCare Technologies (NASDAQ:GEHC) to Strong Sell

GE HealthCare Technologies (NASDAQ:GEHC) was downgraded by equities research analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a report released on Tuesday,Zacks.com reports.

Several other brokerages have also issued reports on GEHC. BNP Paribas Exane decreased their price target on shares of GE HealthCare Technologies from $95.00 to $88.00 in a research note on Friday, May 1st. Citigroup reiterated a “neutral” rating on shares of GE HealthCare Technologies in a research note on Wednesday, July 8th. Jefferies Financial Group reduced their price objective on GE HealthCare Technologies from $105.00 to $90.00 in a report on Thursday, April 30th. Evercore set a $80.00 target price on GE HealthCare Technologies in a research note on Thursday, April 30th. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $85.00 price target on shares of GE HealthCare Technologies in a research report on Thursday, April 30th. Ten research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, GE HealthCare Technologies currently has a consensus rating of “Hold” and a consensus price target of $76.41.

GE HealthCare Technologies Price Performance

GEHC opened at $61.41 on Tuesday. The firm has a market cap of $27.93 billion, a P/E ratio of 14.69, a PEG ratio of 1.69 and a beta of 0.72. The firm has a 50-day moving average of $63.65 and a 200 day moving average of $71.46. The company has a debt-to-equity ratio of 0.95, a quick ratio of 0.95 and a current ratio of 1.22. GE HealthCare Technologies has a fifty-two week low of $58.75 and a fifty-two week high of $89.77.

GE HealthCare Technologies (NASDAQ:GEHC) last announced its quarterly earnings data on Wednesday, April 29th. The company reported $0.99 EPS for the quarter, missing the consensus estimate of $1.07 by ($0.08). The company had revenue of $5.13 billion during the quarter, compared to the consensus estimate of $5.04 billion. GE HealthCare Technologies had a return on equity of 20.46% and a net margin of 9.10%.The business’s revenue was up 7.4% on a year-over-year basis. During the same period in the prior year, the firm posted $1.01 EPS. GE HealthCare Technologies has set its FY 2026 guidance at 4.800-5.000 EPS. On average, research analysts expect that GE HealthCare Technologies will post 4.89 EPS for the current year.

Insider Buying and Selling at GE HealthCare Technologies

In related news, CEO Peter J. Arduini bought 4,169 shares of the company’s stock in a transaction on Thursday, April 30th. The shares were purchased at an average price of $59.92 per share, for a total transaction of $249,806.48. Following the completion of the transaction, the chief executive officer directly owned 259,424 shares in the company, valued at approximately $15,544,686.08. The trade was a 1.63% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Watkin Phoebe L. Yang bought 1,000 shares of the company’s stock in a transaction on Friday, May 8th. The shares were bought at an average price of $63.01 per share, for a total transaction of $63,010.00. Following the transaction, the director owned 13,702 shares of the company’s stock, valued at approximately $863,363.02. This represents a 7.87% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last three months, insiders have purchased 21,847 shares of company stock worth $1,361,355. Company insiders own 0.36% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Laurel Wealth Advisors LLC purchased a new position in GE HealthCare Technologies during the 4th quarter valued at about $26,000. Optima Capital LLC purchased a new stake in shares of GE HealthCare Technologies in the fourth quarter worth about $27,000. Godfrey Financial Associates Inc. bought a new position in shares of GE HealthCare Technologies in the fourth quarter valued at approximately $27,000. Montag A & Associates Inc. boosted its position in shares of GE HealthCare Technologies by 105.4% in the fourth quarter. Montag A & Associates Inc. now owns 341 shares of the company’s stock valued at $28,000 after acquiring an additional 175 shares during the period. Finally, Transamerica Financial Advisors LLC grew its stake in GE HealthCare Technologies by 331.6% during the fourth quarter. Transamerica Financial Advisors LLC now owns 341 shares of the company’s stock valued at $28,000 after acquiring an additional 262 shares in the last quarter. Institutional investors own 82.06% of the company’s stock.

GE HealthCare Technologies Company Profile

GE HealthCare Technologies (NASDAQ: GEHC) is a global medical technology and diagnostics company that develops, manufactures and markets a broad range of products and services for healthcare providers. Its portfolio centers on diagnostic imaging systems, including MRI, CT, PET and X-ray modalities, as well as ultrasound equipment. The company also supplies patient monitoring and anesthesia delivery systems, interventional and surgical imaging solutions, and molecular imaging technologies used in both clinical care and research settings.

In addition to hardware, GE HealthCare offers software, analytics and lifecycle services aimed at improving clinical workflows and equipment uptime.